What is the treatment for urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: June 10, 2025 • View editorial policy

From the Guidelines

The treatment for a urinary tract infection (UTI) should involve short-course antibiotics, with options including nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole for 3 days, or fosfomycin as a single dose for uncomplicated cystitis, and fluoroquinolones or trimethoprim-sulfamethoxazole for pyelonephritis, as recommended by the American College of Physicians 1.

Key Considerations

  • The choice of antibiotic should be based on the type of UTI, with uncomplicated cystitis and pyelonephritis requiring different treatment approaches.
  • The American College of Physicians recommends short-course antibiotics for UTIs, with the goal of minimizing antibiotic use and reducing the risk of resistance 1.
  • For uncomplicated cystitis, nitrofurantoin, trimethoprim-sulfamethoxazole, and fosfomycin are recommended as first-line treatments, with fluoroquinolones reserved for patients with a history of resistant organisms 1.
  • For pyelonephritis, fluoroquinolones or trimethoprim-sulfamethoxazole are recommended, with the choice of antibiotic depending on antibiotic susceptibility 1.

Treatment Options

  • Nitrofurantoin: 100mg twice daily for 5 days
  • Trimethoprim-sulfamethoxazole: DS twice daily for 3 days
  • Fosfomycin: single 3-gram dose
  • Fluoroquinolones: 5-7 days for pyelonephritis ### Additional Recommendations
  • Patients should drink plenty of water to help flush bacteria from the urinary system.
  • Over-the-counter pain relievers such as ibuprofen or acetaminophen can help manage discomfort.
  • Symptoms usually improve within 1-2 days of starting antibiotics, but the full course must be completed to prevent recurrence.
  • For recurrent or complicated UTIs, longer treatment courses or different antibiotics may be needed, as recommended by the AUA/CUA/SUFU guideline 2.

From the FDA Drug Label

To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. Urinary Tract Infections For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination

The treatment for urinary tract infection (UTI) includes the use of antibacterial agents such as trimethoprim-sulfamethoxazole or ciprofloxacin.

  • The choice of antibacterial agent should be based on culture and susceptibility information.
  • Trimethoprim-sulfamethoxazole is effective against susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris.
  • Ciprofloxacin is also effective in treating UTIs, including complicated urinary tract infections and pyelonephritis in pediatric patients 3. It is recommended to use a single effective antibacterial agent for initial episodes of uncomplicated UTIs 4.

From the Research

Treatment Options for Urinary Tract Infections (UTIs)

The treatment of UTIs depends on the type of bacteria causing the infection and the severity of the symptoms. According to 5, the recommended first-line empiric antibiotic therapy for acute uncomplicated bacterial cystitis in otherwise healthy adult nonpregnant females is a 5-day course of nitrofurantoin, a 3-g single dose of fosfomycin tromethamine, or a 5-day course of pivmecillinam.

Antibiotic Resistance and Treatment

Antibiotic resistance is a growing concern in the treatment of UTIs. As stated in 6, resistance to cotrimoxazole (trimethoprim/sulfamethoxazole) has made the empirical use of this drug problematic in many geographical areas. If local uropathogen resistance rates to cotrimoxazole exceed 10-25%, empirical cotrimoxazole therapy should not be utilized.

Specific Treatment Regimens

Some specific treatment regimens for UTIs include:

  • Nitrofurantoin: 5-7 days of treatment 7, 8
  • Trimethoprim-sulfamethoxazole: 3 days of treatment 6, 8
  • Fosfomycin tromethamine: single 3-g dose 5, 8
  • Fluoroquinolones: reserved for more invasive infections 8
  • β-Lactam agents: not as effective as empirical first-line therapies 8

Special Considerations

Some patient populations may require special consideration when treating UTIs, including:

  • Pregnant women: not included in the recommended first-line empiric antibiotic therapy 5
  • Men: may require 7 to 14 days of therapy for acute urinary tract infection 8
  • Women with diabetes: should be treated similarly to women without diabetes, unless they have voiding abnormalities 8

Key Points to Consider

When treating UTIs, it is essential to consider the following key points:

  • Knowledge of common uropathogens and local susceptibility patterns is crucial in determining appropriate empiric antibiotic therapy 5
  • Antibiotic resistance rates should be taken into account when choosing an empirical regimen 6, 9
  • Individualized assessment of risk factors for resistance and regimen tolerability is needed to choose the optimum empirical regimen 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.